Focused On-demand Libraries - Receptor.AI Collaboration


Explore the Potential with AI-Driven Innovation

The specialised, focused library is developed on demand with the most recent virtual screening and parameter assessment technology, guided by the Receptor.AI drug discovery platform. This approach exceeds the capabilities of traditional methods and offers compounds with higher activity, selectivity, and safety.


From a virtual chemical space containing more than 60 billion molecules, we precisely choose certain compounds. Reaxense aids in their synthesis and provision.


The library features a range of promising modulators, each detailed with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Plus, each compound is presented with its ideal docking poses, affinity scores, and activity scores, ensuring a thorough insight.


Our high-tech, dedicated method is applied to construct targeted libraries for enzymes.


 

Fig. 1. The screening workflow of Receptor.AI

The procedure entails thorough molecular simulations of the catalytic and allosteric binding pockets, accompanied by ensemble virtual screening that factors in their conformational flexibility. When developing modulators, the structural modifications brought about by reaction intermediates are factored in to optimize activity and selectivity.


Key features that set our library apart include:


  • The Receptor.AI platform integrates extensive information about the target protein, such as historical experiments, academic research, known ligands, and structural insights, thereby increasing the likelihood of identifying highly relevant compounds.

  • The platform’s sophisticated molecular simulations are designed to discover potential binding sites, ensuring that our focused library is optimal for the discovery of allosteric inhibitors and binders for cryptic pockets.

  • With over 50 customisable AI models, verified through extensive testing in commercial drug discovery and research, Receptor.AI is efficient, reliable, and precise. These models are essential in the production of our focused libraries.

  • Receptor.AI not only produces focused libraries but also provides full services and solutions at every stage of preclinical drug discovery, with a success-based pricing structure that aligns our interests with the success of your project.


PARTNER
Receptor.AI
 
UPACC
O00167

UPID:
EYA2_HUMAN

ALTERNATIVE NAMES:
-

ALTERNATIVE UPACC:
O00167; Q5JSW8; Q86U84; Q96CV6; Q96H97; Q99503; Q99812; Q9BWF6; Q9H4S3; Q9H4S9; Q9NPZ4; Q9UIX7

BACKGROUND:
The protein Eyes absent homolog 2 (EYA2) functions as both a phosphatase and transcriptional coactivator, playing a pivotal role in DNA repair and organ development. It specifically targets 'Tyr-142' of histone H2AX for dephosphorylation, promoting the recruitment of DNA repair complexes. Additionally, EYA2 collaborates with SIX1 and DACH2 in hypaxial muscle development, highlighting its functional overlap with EYA1.

THERAPEUTIC SIGNIFICANCE:
Exploring the multifunctional role of Eyes absent homolog 2 offers promising avenues for developing therapeutic interventions, particularly in the realms of DNA repair and muscle development.

Looking for more information on this library or underlying technology? Fill out the form below and we will be in touch with all the details you need.